Delisting risk
CytoMed Therapeutics
Develops donor-derived and iPSC-based cell therapies for cancer.
$0.9200
After-hours close0.00 (0.00%)
At close$0.9200(−3.16%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 5.82%
Shares outstanding 11.83M · Float 3.49M · 29.5% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Choo Chee Kong | 24.30% | 2.90M | 13D | Jul 24, 2026 ↗ |
| mDR LTD | 11.33% | 1.31M | 13G | Mar 24, 2025 ↗ |
| 28 Consultants Ltd | 7.62% | 880.3K | 13G | Mar 4, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Chee Kong Choo | director, 10 percent owner: | 630.3K | 5.33% | Jul 24, 2026 |
| Yvonne Goh | officer: Chief Financial Officer | 25.8K | 0.22% | May 15, 2026 |
| Yoong Ying Tan | officer: Chief Corporate Officer | 25.8K | 0.22% | May 15, 2026 |
| Keng Kiat Toh | director | 4.0K | 0.03% | May 26, 2026 |
| Chak Hua Yew | director | 2.5K | 0.02% | May 15, 2026 |
2 ten-percent owners hold 5.54M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (681.8K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 14, 2026 | Chee Kong Choodirector, 10 percent owner: | Purchase · 2 lots | 200,000 | $1.50 | 530,324 |
| Jul 20, 2026 | Chee Kong Choodirector, 10 percent owner: | Purchase · 2 lots | 200,000 | $1.50 | 630,324 |
| May 13, 2026 | Chee Kong Choodirector, 10 percent owner: | Purchase | 112,000 | $1.15 | 430,324 |
CongressHouse and Senate disclosures
Not reported.